AMPH - Amphastar Pharmaceuticals, Inc.
IEX Last Trade
37.76
-0.110 -0.291%
Share volume: 2,540
Last Updated: Fri 27 Dec 2024 04:29:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.05%
PREVIOUS CLOSE
CHG
CHG%
$37.87
-0.11
-0.29%
Fundamental analysis
48%
Profitability
60%
Dept financing
32%
Liquidity
75%
Performance
32%
Performance
5 Days
-2.17%
1 Month
-13.46%
3 Months
-20.07%
6 Months
-4.40%
1 Year
-38.78%
2 Year
33.48%
Key data
Stock price
$37.76
DAY RANGE
$37.87 - $38.26
52 WEEK RANGE
$37.48 - $65.92
52 WEEK CHANGE
-$38.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Yong F. Zhang
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs.
Recent news